Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

NCT01281865 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Adult Synovial Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions

OTHER: diagnostic laboratory biomarker analysis
DRUG: everolimus
DRUG: imatinib mesylate

Sponsor

National Cancer Institute (NCI)